Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endearavors.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The goal of the SNMMI Best Practices in Preclinical Imaging Initiative is to provide guidelines based on the community experience in designing and conducting preclinical imaging experiments.
Available Resources Include:
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
Biomarkers built upon aptamers rather than peptides and antibodies offer multiple advantages for molecular imaging and several are currently under development, according to a review published Feb. 13 in the Journal of Nuclear Medicine.
(SNMMI in the News)
A treatment strategy for colon cancer combining molecular imaging, a radioimmunotherapy that seeks colon-specific anatomy and concomitant chemotherapy is being bundled as chemoradiotherapy to take out more metastatic disease, according to a study published online Feb. 20 in the Journal of Nuclear Medicine.
(SNMMI in the News)
Researchers from the University of Manchester have shown promising results for a new treatment approach in follicular lymphoma, a type of non-Hodgkin’s lymphoma.
(MI: Making a Difference)
CMS has released instructions to Medicare Administrative Contractors regarding the processing of claims pursuant to the June 11, 2013 final decision to end the coverage with evidence development (CED) requirement for certain FDG PET studies for solid tumors.
(Government Relations News)